PBM
HRTX icon

Propel Bio Management’s Heron Therapeutics HRTX Stock Holding History

Propel Bio Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-104,195
Closed -$177K – 33
2023
Q4 		$177K Buy
+104,195
New +$115K 0.15% 32

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Propel Bio Management's HRTX Position: Q1 2024 in Review

Propel Bio Management sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 104,195 shares — an estimated $177K sold.

Propel Bio Management first reported a position in HRTX in Q4 2023 and held it in 1 quarter. The position peaked at $177K in Q4 2023. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • Propel Bio Management reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Propel Bio Management sold 104,195 Heron Therapeutics shares in Q1 2024, an estimated $177K.
  • Propel Bio Management first reported a position in Heron Therapeutics in Q4 2023 and held it in 1 quarter.
  • Propel Bio Management's Heron Therapeutics position peaked at $177K in Q4 2023.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on Propel Bio Management's 13F filing for Q1 2024, filed 13 May 2024.